Page last updated: 2024-08-16

riluzole and Disease Models, Animal

riluzole has been researched along with Disease Models, Animal in 125 studies

Research

Studies (125)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (8.80)	18.2507
2000's	46 (36.80)	29.6817
2010's	60 (48.00)	24.3611
2020's	8 (6.40)	2.80

Authors

Authors	Studies
Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ	1
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV	1
Cawley, NX; Cougnoux, A; Fellmeth, M; Navid, F; Porter, FD; Serra-Vinardell, J; Wassif, CA; Yerger, JC	1
Patel, AB; Saba, K	1
Bartke, A; Cox, MF; Findley, CA; Hascup, ER; Hascup, KN; McFadden, SA; Peck, MR; Quinn, K; Sime, LN	1
Chen, M; Deng, Y; Li, RW; Pham, HN; Smith, PN; Weiss, S	1
Bi, F; Chen, S; Huang, C; Liao, Q; Lu, K; Zhou, J	1
Janikova, M; Mainerova, K; Petrasek, T; Stuchlik, A; Svoboda, J; Vojtechova, I	1
Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL	1
Caballero-Hernandez, DE; Cejudo-Guillén, M; Franco, JM; Gomez-Zumaquero, JM; Jimenez-Pacheco, A; Lopez, S; Magdalena Leal-Lasarte, M; Pozo, D	1
Chen, S; Feun, LG; Kandemir, H; Kuo, MT; Li, YY; Nguyen, DJM; Prince, JS; Savaraj, N; Shah, S; Wangpaichitr, M; Wu, C	1
Abaei, A; Boeckers, TM; Fegert, JM; Hengerer, B; Nespoli, E; Rasche, V; Rizzo, F	1
Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD	1
Egashira, N; Higuchi, H; Kawashiri, T; Masuda, S; Masuguchi, K; Mitsuyasu, S; Ono, Y; Ozawa, N; Ushio, S; Yamamoto, S	1
Altunrende, ME; Aydoseli, A; Can, H; Dolgun, M; Göker, B; Gömleksiz, C; Sencer, A	1
Coughlan, KS; Halang, L; Hogg, MC; Prehn, JHM; Woods, I	1
Al-Beyati, ESM; Bahadir, B; Caglar, YS; Cansiz, C; Demirel, A; Dogan, I; Eroglu, U; Huseynov, R; Kilinc, MC; Ozgural, O	1
Ji, G; Neugebauer, V; Thompson, JM; Yakhnitsa, V	1
Jaiswal, MK	1
Gray, JD; Kazim, SF; Larson, CS; McEwen, BS; Okamoto, M; Pereira, AC; Soya, H	1
Feng, L; Gao, M; Ma, X; Mao, A; Wong, WT; Xie, M; Yao, X; Zhou, T; Zhu, Y	1
Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J	1
Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J	1
Arai, T; Giles, AC; Ikenaka, K; Katsuno, M; Kawai, K; Mochizuki, H; Mori, I; Nakadera, Y; Nakano, S; Sobue, G; Tsukada, Y	1
Chapela, D; Corte-Real, S; Cristóvão, AM; Martins, I; Pinto, P; Saúde, L; Sousa, S	1
Buttigieg, J; Chow, DS; Fehlings, MG; Satkunendrarajah, K; Teng, Y; Wu, Y	1
Dimitriadi, M; Hart, AC; Kalloo, G; Kye, MJ; Sahin, M; Yersak, JM	1
Li, J; Rutkove, SB; Sung, M	1
Bowser, R; Friedlander, RM; Li, W; Pandya, RS; Wang, X; Zhu, H	1
Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR	1
Dahlstrom, JE; Saint, DA; Weiss, SM	1
Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K	1
Carbonara, R; Conte Camerino, D; Costanza, T; Desaphy, JF	1
Carlstedt, T; Chew, DJ; Shortland, PJ	1
Sari, Y; Yacila, G	1
de Carvalho, M; Pinto, S; Pronto-Laborinho, AC	1
Brown, BM; Cao, Z; Chen, YJ; Coleman, N; Goldin, AL; Jenkins, DP; Nguyen, HM; Pessah, IN; Rogawski, MA; Tanaka, BS; Wulff, H; Zolkowska, D	1
Bertz, J; Gladbach, A; Ittner, AA; Ittner, LM; Suh, LS	1
Chen, S; Goydos, JS; Haffty, B; Khan, A; Wall, BA; Yu, LJ	1
Cengiz, A; Emre, E; Kürşat Yıldız, D; Pirhan, D; Yüksel, N	1
Cryan, JF; Glennon, J; Moloney, RD; O'Connor, RM; Vlachou, S	1
Gerzanich, V; Hosier, H; Ivanova, S; Keledjian, K; Peterson, D; Popovich, PG; Simard, JM; Smith, BR; Tsymbalyuk, O	1
Ji, G; Neugebauer, V; Thompson, JM	1
Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L	1
Hickman, JE; Hunsberger, HC; Reed, MN	1
Moujalled, D; White, AR	1
Golla, M; Hübener-Schmid, J; Lehmann, L; Riess, O; Schmidt, J; Schmidt, T; Weber, JJ	1
Davidson, RL; Gray, JD; Kogan, JF; McEwen, BS; Morrison, JH; Okamoto, M; Pereira, AC; Rubin, TG	1
Baruscotti, M; Benedetti, L; Bucchi, A; De Maglie, M; Del Giacco, L; Francolini, M; Ghilardi, A; Perego, C; Prosperi, L; Rottoli, E	1
Abdolmaleki, A; Behnam-Rassouli, M; Ghayour, MB	1
Boucherie, C; Caumont, AS; Hermans, E; Maloteaux, JM	1
Banasr, M; Behar, KL; Chowdhury, GM; Duman, RS; Newton, SS; Sanacora, G; Terwilliger, R	1
Aziz, NA; Brundin, P; Landwehrmeyer, GB; Roos, RA; Stijnen, T; van der Burg, JM	1
Carunchio, I; Curcio, L; Mercuri, NB; Pieri, M; Zona, C	1
Sanacora, G; Valentine, GW	1
Fong, AY; Marshall, LH; Milsom, WK	1
Danesh-Meyer, HV; Levin, LA	1
Brunet, N; Calderó, J; Esquerda, JE; Tarabal, O	1
Durand, J; Gueritaud, JP; Pambo-Pambo, A	1
Sanacora, G	1
Bensimon, G; Buyse, M; Dupuis, L; Farinotti, R; Fernandez, C; Loeffler, JP; Meininger, V; Milane, A	1
Inagaki, M; Iwai, T; Murasawa, H; Nakatani, A; Saitoh, A; Takahashi, K; Yamada, M; Yamaguchi, K; Yoshida, M	1
Alagramam, KN; Frankel, JK; Heddon, CM; Levitt, AH; Megerian, CA; Melki, SJ; Momin, SR	1
Cadotte, DW; Fehlings, MG	1
Espitia, JW; Gourley, SL; Sanacora, G; Taylor, JR	1
Eisenach, JC; Hayashida, K; Hobo, S	1
Fu, R; Heckman, CJ; Schuster, JE; Siddique, T	1
Chow, JC; Huang, CW; Tsai, JJ; Wu, SN	1
Gerzanich, V; Ivanov, A; Ivanova, S; Keledjian, K; Simard, JM; Tsymbalyuk, O	1
Carbone, M; Duty, S; Rattray, M	1
Cho, W; Gwag, BJ; Im, DS; Lee, JH; Lee, JK; Lee, YA; Lee, YB; Shin, JH; Springer, JE; Yun, BS	1
Nag, N; Storey, E; Tarlac, V	1
Bloch, KE; Jung, HH; Neumann, M	1
Dulin, JN; Grill, RJ; Moore, ML	1
Linden, DR	1
Aarabi, B; Fehlings, MG; Grossman, RG; Guest, J; Harrop, JS; Hashimoto, R; Norvell, D; Raich, A; Tator, CH	1
Al Mashhadi, S; Beattie, CE; Lyon, AN; McDearmid, JR; McGown, A; Panagiotaki, N; Ramesh, TM; Redhead, N; Shaw, PJ; Tong, H	1
Pascuzzi, RM	1
Ariano, MA; Calvert, CR; Cepeda, C; Christian, LJ; Hernández-Echeagaray, E; Hurst, RS; Jocoy, E; Levine, MS; Nguyen, OK	1
Beal McIlvain, H; Dunlop, J; Howland, DS; She, Y	1
Gowing, G; Julien, JP; Kriz, J	1
da Silva, S; Jiang, F; Snow, RJ; Tarnopolsky, MA; Turnbull, J	1
Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I	1
Bates, GP; Hockly, E	1
Dall'Igna, OP; Dietrich, MO; Hoffmann, A; Lara, DR; Lourenço Da Silva, A; Souza, DO	1
Gilgun-Sherki, Y; Melamed, E; Offen, D; Panet, H	1
Anand, P; Bergerot, A; Carlstedt, T; Hunt, SP; Shortland, PJ	1
Guitton, MJ; Puel, JL; Wang, J	1
Blaugrund, E; Ludolph, AC; Malessa, S; Reuter, A; Waibel, S	1
Kunst, CB	1
Borowicz, KK; Czuczwar, SJ; Drelewska, E; Rwiader, M	1
Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK	1
Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A	1
Barker, AL; Bates, GP; Beunard, JL; Hockly, E; Holt, K; Lowden, PA; Moffitt, H; Moolman, DL; Revington, AP; Sathasivam, K; Sunshine, S; Tse, J; Wanker, EE; Woodman, B	1
Hyun, HJ; Koh, JY; Yoo, MH; Yoon, YH	1
Barbera, S; Bigini, P; De Paola, M; Fumagalli, E; Mennini, T	1
Leinster, VH; Robson, LG; Shortland, PJ; White, W	1
Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS	1
Choi, HC; Choi, SY; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Kwak, SE; Kwon, OS; Song, HK	1
Ates, O; Cakir, CO; Cayli, SR; Gurses, I; Kocak, A; Tarim, O; Turkoz, Y	1
Costa, HJ; Costa, MP; da Silva, CF; Lazarini, PR	1
Caress, J; Gifondorwa, DJ; Hayes, CD; Milligan, CE; Oppenheim, RW; Prevette, DM; Robinson, MB; Taylor, AR	1
Cho, KS; Chung, H; Koh, JY; Yoo, MH; Yoon, YH	1
Allene, C; Amendola, J; Bories, C; Durand, J; Gueritaud, JP; Lamotte d'Incamps, B; Liabeuf, S; Pambo-Pambo, A	1
Dengler, R; Kollewe, K; Petri, S	1
Obrenovitch, TP	1
Gernert, M; Löscher, W; Richter, A	1
Fleck, TJ; Gurney, ME; Hall, ED; Himes, CS	1
Hall, ED; Smith, SL	1
Bezard, E; Boireau, A; Boraud, T; Gross, CE; Imbert, C; Stutzmann, JM	1
Bernardi, G; Calabresi, P; Centonze, D; Marfia, GA; Marinelli, S; Pisani, A	1
Kanthasamy, AG; Nguyen, B; Truong, DD; Yun, RJ	1
Heurteaux, C; Lang-Lazdunski, L; Lazdunski, M; Vaillant, N; Widmann, C	1
Miyamoto, KJ; Miyamoto, TA	1
Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S	1
Bae, HJ; Gu, JS; Kang, DW; Koo, JS; Lee, YS; Roh, JK; Yoon, BW	1
Bodewits, P; de Haan, P; Dzoljic, M; Jacobs, MJ; Kalkman, CJ; Lips, J; Vanicky, I	1
Bejuit, R; Bohme, GA; Gallix, P; Imperato, A; Kennel, P; Pratt, J; Revah, F; Stutzmann, JM	1
Ludolph, AC	1
Blanchard, V; Imperato, A; Moussaoui, S; Obinu, MC; Reibaud, M	1
Morrison, KE	1
Dib, M; Eybalin, M; Hameg, A; Lenoir, M; Puel, JL; Pujol, R; Vago, P; Wang, J	1
Agid, Y; Blanchard, V; Bohme, GA; Debeir, T; Do, L; Douhou, A; Dufour, N; Moussaoui, S; Murer, MG; Raisman-Vozari, R	1
Bardot, F; Blanchard, JC; Laduron, PM; Pratt, J; Rataud, J; Roux, M; Stutzmann, JM	1
Gottesmann, C; Lazdunski, M; Romettino, S	1

Reviews

17 review(s) available for riluzole and Disease Models, Animal

Article	Year
Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. Advances in experimental medicine and biology, 2017, Volume: 978 Topics: Acetylation; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA Methylation; Environmental Exposure; Epigenesis, Genetic; Gene Expression Regulation; Gene-Environment Interaction; Histone Code; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; MicroRNAs; Motor Neurons; Mutation; Oxidative Stress; Protein Processing, Post-Translational; Riluzole; Superoxide Dismutase-1	2017
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Medicinal research reviews, 2019, Volume: 39, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Design; Edaravone; Humans; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species; Riluzole	2019
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cellular and molecular life sciences : CMLS, 2013, Volume: 70, Issue:24 Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease Models, Animal; Disease Progression; Humans; Mice; Mitochondria; Motor Neurons; Mutant Proteins; Neuroprotective Agents; Proteolysis; Riluzole; Superoxide Dismutase	2013
Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. BioMed research international, 2014, Volume: 2014 Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Brain Stem; Cell Movement; Disease Models, Animal; Humans; Motor Cortex; Neuroprotective Agents; Receptors, Vascular Endothelial Growth Factor; Riluzole; Spinal Cord; Vascular Endothelial Growth Factor B	2014
Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. CNS drugs, 2016, Volume: 30, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Mutation; Riluzole	2016
Neuroprotection: extrapolating from neurologic diseases to the eye. American journal of ophthalmology, 2009, Volume: 148, Issue:2 Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino Acid Antagonists; Glaucoma, Open-Angle; Humans; Memantine; N-Methylaspartate; Nervous System Diseases; Neuroprotective Agents; Optic Nerve Diseases; Riluzole	2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10 Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Design; Humans; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Rats; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Riluzole; Synaptic Transmission	2009
Spinal cord injury: a systematic review of current treatment options. Clinical orthopaedics and related research, 2011, Volume: 469, Issue:3 Topics: Animals; Decompression, Surgical; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Neuroprotective Agents; Recovery of Function; rho-Associated Kinases; Riluzole; Spinal Cord Injuries; Trauma, Nervous System	2011
[Amyotrophic lateral sclerosis--diagnosis and treatment]. Praxis, 2012, Jul-04, Volume: 101, Issue:14 Topics: Activities of Daily Living; Aged; Amyotrophic Lateral Sclerosis; Animals; Cause of Death; Cross-Sectional Studies; Diagnosis, Differential; Disease Models, Animal; DNA Mutational Analysis; Excitatory Amino Acid Antagonists; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Motor Neurons; Neurologic Examination; Palliative Care; Riluzole; Spinal Cord; Survival Analysis; TDP-43 Proteinopathies	2012
Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury. Journal of neurosurgery. Spine, 2012, Volume: 17, Issue:1 Suppl Topics: Animals; Disease Models, Animal; Glyburide; Humans; Magnesium Sulfate; Minocycline; Neuroprotective Agents; Nimodipine; Riluzole; Spinal Cord Injuries; Translational Research, Biomedical	2012
ALS, motor neuron disease, and related disorders: a personal approach to diagnosis and management. Seminars in neurology, 2002, Volume: 22, Issue:1 Topics: Adolescent; Adult; Animals; Case Management; Combined Modality Therapy; Creatine; Diagnosis, Differential; Diagnostic Tests, Routine; Disease Models, Animal; Enteral Nutrition; Female; Humans; Male; Mice; Middle Aged; Motor Neuron Disease; Muscular Atrophy, Spinal; Neurologic Examination; Physical Therapy Modalities; Quality of Life; Respiration, Artificial; Riluzole; Tracheostomy	2002
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Current opinion in neurology, 2003, Volume: 16, Issue:4 Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Peptides; Point Mutation; Riluzole; Thioctic Acid; Trinucleotide Repeats; Ubiquinone	2003
Complex genetics of amyotrophic lateral sclerosis. American journal of human genetics, 2004, Volume: 75, Issue:6 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Apolipoproteins E; Ciliary Neurotrophic Factor; Disease Models, Animal; Gene Expression Regulation; Humans; Mice; Neurofilament Proteins; Receptors, Glutamate; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A	2004
[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms]. Der Nervenarzt, 2008, Volume: 79, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Riluzole	2008
Sodium and potassium channel modulators: their role in neuroprotection. International review of neurobiology, 1997, Volume: 40 Topics: Animals; Benzeneacetamides; Cell Survival; Disease Models, Animal; Lamotrigine; Neurons; Neuroprotective Agents; Piperazines; Piperidines; Potassium Channels; Pyrimidines; Riluzole; Sodium Channels; Thiazoles; Triazines	1997
Treatment of amyotrophic lateral sclerosis--what is the next step? Journal of neurology, 2000, Volume: 247 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Mutation; Neuroprotective Agents; Riluzole; Superoxide Dismutase	2000
Therapies in amyotrophic lateral sclerosis-beyond riluzole. Current opinion in pharmacology, 2002, Volume: 2, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Hypoxia; Disease Models, Animal; Humans; Neuroprotective Agents; Riluzole	2002

Trials

2 trial(s) available for riluzole and Disease Models, Animal

Article	Year
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. Science translational medicine, 2015, Dec-02, Volume: 7, Issue:316 Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Motor Neurons; Neuroprotective Agents; Prospective Studies; Rats; Reperfusion Injury; Riluzole; Spinal Cord; Spinal Cord Diseases; Spondylosis; Treatment Outcome	2015
Weight loss in Huntington disease increases with higher CAG repeat number. Neurology, 2008, Nov-04, Volume: 71, Issue:19 Topics: Adult; Aged; Animals; Body Mass Index; Body Weight; Disease Models, Animal; Energy Intake; Female; Humans; Huntingtin Protein; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Placebos; Riluzole; Trinucleotide Repeats; Weight Loss	2008

Article

Year

Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.

Science translational medicine, 2015, Dec-02, Volume: 7, Issue:316

Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Motor Neurons; Neuroprotective Agents; Prospective Studies; Rats; Reperfusion Injury; Riluzole; Spinal Cord; Spinal Cord Diseases; Spondylosis; Treatment Outcome

2015

Weight loss in Huntington disease increases with higher CAG repeat number.

Neurology, 2008, Nov-04, Volume: 71, Issue:19

Topics: Adult; Aged; Animals; Body Mass Index; Body Weight; Disease Models, Animal; Energy Intake; Female; Humans; Huntingtin Protein; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Placebos; Riluzole; Trinucleotide Repeats; Weight Loss

2008

Other Studies

106 other study(ies) available for riluzole and Disease Models, Animal

Article	Year
Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Science translational medicine, 2019, 07-10, Volume: 11, Issue:500 Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries	2019
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection	2020
Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1. Molecular genetics and metabolism, 2021, Volume: 134, Issue:4 Topics: Animals; Astrocytes; Ceftriaxone; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Female; Glutamic Acid; Humans; Male; Mice; Mice, Inbred BALB C; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Riluzole	2021
Riluzole restores memory and brain energy metabolism in AβPP-PS1 mouse model of Alzheimer's disease. Biochemical and biophysical research communications, 2022, 06-25, Volume: 610 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Energy Metabolism; Glucose; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Presenilin-1; Riluzole	2022
Prodromal Glutamatergic Modulation with Riluzole Impacts Glucose Homeostasis and Spatial Cognition in Alzheimer's Disease Mice. Journal of Alzheimer's disease : JAD, 2023, Volume: 94, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition; Disease Models, Animal; Female; Glucose; Homeostasis; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Riluzole	2023
Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. Injury, 2020, Volume: 51, Issue:2 Topics: Animals; Apoptosis; Disease Models, Animal; Muscle, Skeletal; Random Allocation; Reperfusion Injury; Riluzole; Swine	2020
Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis. Current neurovascular research, 2020, Volume: 17, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Humans; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Riluzole; Treatment Outcome	2020
Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task. Biomolecules, 2021, 07-09, Volume: 11, Issue:7 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Male; Memantine; Memory; Obsessive-Compulsive Disorder; Rats; Rats, Long-Evans; Riluzole; Spatial Learning	2021
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. The European journal of neuroscience, 2021, Volume: 54, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Female; Mice; Mice, Transgenic; Neurodegenerative Diseases; Riluzole	2021
Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget, 2017, Jul-25, Volume: 8, Issue:30 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Energy Metabolism; Gene Expression; Glucose; Glutamic Acid; Glutamine; Glycolysis; Heterografts; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Lung Neoplasms; Mice; Mitochondria; Models, Biological; NAD; Oxidation-Reduction; Oxidative Stress; Oxygen Consumption; Reactive Oxygen Species; Receptors, Metabotropic Glutamate; Riluzole	2017
Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal Translational psychiatry, 2017, 08-01, Volume: 7, Issue:8 Topics: Animals; Antipsychotic Agents; Aripiprazole; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Disease Models, Animal; Glutamic Acid; Magnetic Resonance Spectroscopy; Male; Motor Activity; Neuroprotective Agents; Rats; Rats, Inbred WKY; Riluzole	2017
Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. Neuroscience letters, 2017, Sep-29, Volume: 658 Topics: Amyotrophic Lateral Sclerosis; Animals; Diazepam; Disease Models, Animal; Hippocampus; Mice, Inbred C57BL; Neurodegenerative Diseases; Riluzole	2017
Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Scientific reports, 2017, 08-29, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Biological Transport; Chemoprevention; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamates; Hyperalgesia; Oxaliplatin; Rats; Riluzole; Treatment Outcome	2017
Combined and individual use of pancaspase inhibitor Q-VD-OPh and NMDA receptor antagonist riluzole in experimental spinal cord injury. Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2017, Volume: 23, Issue:6 Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Disease Models, Animal; Male; Necrosis; Neuroprotective Agents; Quinolines; Rats; Rats, Sprague-Dawley; Riluzole; Spinal Cord Injuries	2017
Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic lateral sclerosis & frontotemporal degeneration, 2018, Volume: 19, Issue:5-6 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; DNA-Binding Proteins; Kaplan-Meier Estimate; Longevity; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Riluzole; RNA-Binding Protein FUS; Superoxide Dismutase	2018
Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury. World neurosurgery, 2018, Volume: 114 Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Laminectomy; Locomotion; Male; Myelin Sheath; Nerve Regeneration; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Riluzole; Severity of Illness Index; Spinal Cord Injuries	2018
Small conductance calcium activated potassium (SK) channel dependent and independent effects of riluzole on neuropathic pain-related amygdala activity and behaviors in rats. Neuropharmacology, 2018, Volume: 138 Topics: Analgesics, Non-Narcotic; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Male; Membrane Potentials; Neural Inhibition; Neuralgia; Neurotransmitter Agents; Pain Threshold; Random Allocation; Rats, Sprague-Dawley; Riluzole; Small-Conductance Calcium-Activated Potassium Channels; Spinal Nerves; Synaptic Transmission; Tissue Culture Techniques; Vocalization, Animal	2018
Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer's disease. Translational psychiatry, 2018, 08-14, Volume: 8, Issue:1 Topics: Alzheimer Disease; Animals; Astrocytes; Cognition; Disease Models, Animal; Gene Expression; Hippocampus; Male; Memory; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Plaque, Amyloid; Receptors, N-Methyl-D-Aspartate; Riluzole; Sequence Analysis, RNA	2018
The TRPC5 channel regulates angiogenesis and promotes recovery from ischemic injury in mice. The Journal of biological chemistry, 2019, 01-04, Volume: 294, Issue:1 Topics: Animals; Disease Models, Animal; Endothelial Cells; HEK293 Cells; Humans; Ischemia; Mice; Mice, Knockout; Neovascularization, Pathologic; Retinal Diseases; Riluzole; TRPC Cation Channels	2019
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model. Molecular neurobiology, 2019, Volume: 56, Issue:7 Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole	2019
No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. Physiology & behavior, 2019, 05-15, Volume: 204 Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagonists; Learning; Male; Memantine; Motor Activity; Obsessive-Compulsive Disorder; Quinpirole; Rats; Rats, Long-Evans; Riluzole	2019
A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease. Scientific reports, 2019, 07-12, Volume: 9, Issue:1 Topics: Amyotrophic Lateral Sclerosis; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Drug Evaluation, Preclinical; Dynactin Complex; Humans; Motor Neurons; Neuroprotective Agents; Nifedipine; Riluzole	2019
A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals. Scientific reports, 2019, 07-19, Volume: 9, Issue:1 Topics: Animals; Cycloserine; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Female; Locomotion; Mice; Mice, Inbred C57BL; Minocycline; Riluzole; Spinal Cord Injuries; Tranexamic Acid; Zebrafish	2019
Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. Journal of neurotrauma, 2013, Mar-15, Volume: 30, Issue:6 Topics: Animals; Cervical Vertebrae; Disease Models, Animal; Drug Evaluation, Preclinical; Evoked Potentials, Somatosensory; Female; Motor Activity; Neuroprotective Agents; Rats; Rats, Wistar; Riluzole; Spinal Cord Injuries; Time Factors	2013
The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Apr-10, Volume: 33, Issue:15 Topics: Animals; Axons; Caenorhabditis elegans; Cells, Cultured; Disease Models, Animal; Gene Knockdown Techniques; Hippocampus; Muscular Atrophy, Spinal; Mutation; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Riluzole; Small-Conductance Calcium-Activated Potassium Channels; Survival of Motor Neuron 1 Protein	2013
Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PloS one, 2013, Volume: 8, Issue:6 Topics: Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Electric Impedance; Female; Male; Mice; Motor Activity; Motor Neurons; Muscle Strength; Muscle, Skeletal; Myography; Neuroprotective Agents; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1	2013
Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. Neurobiology of disease, 2014, Volume: 62 Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gait; Hyperalgesia; Neuralgia; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Riluzole; Spinal Cord Diseases; Spondylosis	2014
Riluzole reduces arrhythmias and myocardial damage induced by coronary occlusion in anaesthetized pigs. Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:12 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Occlusion; Disease Models, Animal; Electrocardiography; Female; Male; Myocardial Ischemia; Myocardium; Riluzole; Sodium Channel Blockers; Swine	2013
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. Journal of neurosurgery, 2014, Volume: 120, Issue:4 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Excitatory Amino Acid Antagonists; Glioma; Memantine; Mice; Polymers; Rats; Riluzole	2014
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. Experimental neurology, 2014, Volume: 255 Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle, Skeletal; Myotonia Congenita; Orphenadrine; Piperidines; Propafenone; Rats; Rats, Wistar; Riluzole; Sodium Channel Blockers; Thiazoles	2014
The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. The journal of pain, 2014, Volume: 15, Issue:6 Topics: Animals; Disease Models, Animal; Functional Laterality; Hyperalgesia; Male; Minocycline; Neurons; Neuroprotective Agents; Pain; Pain Threshold; Phosphopyruvate Hydratase; Rats; Rats, Wistar; Riluzole; Spinal Cord Injuries; Spinal Nerve Roots; Time Factors	2014
Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Current medicinal chemistry, 2014, Volume: 21, Issue:31 Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Biomarkers; Cell- and Tissue-Based Therapy; Disease Models, Animal; Genetic Therapy; Humans; Immunotherapy; Nerve Growth Factors; Riluzole; Stem Cell Transplantation	2014
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015, Volume: 12, Issue:1 Topics: Animals; Anticonvulsants; Disease Models, Animal; Male; Mice; Pain Threshold; Rats; Rats, Sprague-Dawley; Riluzole; Seizures; Voltage-Gated Sodium Channels	2015
p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's disease. Acta neuropathologica communications, 2014, Oct-21, Volume: 2 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Dizocilpine Maleate; Electrodes, Implanted; Electroencephalography; Enzyme Inhibitors; Epilepsy; Excitatory Amino Acid Antagonists; Gamma Rhythm; Hippocampus; Imidazoles; Male; Mice, Inbred C57BL; Mice, Transgenic; p38 Mitogen-Activated Protein Kinases; Pyridines; Receptors, N-Methyl-D-Aspartate; Riluzole; Theta Rhythm	2014
Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment cell & melanoma research, 2015, Volume: 28, Issue:1 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Clone Cells; Disease Models, Animal; Humans; Luciferases; Luminescence; Melanoma; Mice; Radiation-Sensitizing Agents; Receptors, Metabotropic Glutamate; Riluzole; Tumor Burden; Xenograft Model Antitumor Assays	2015
Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. Current eye research, 2016, Volume: 41, Issue:1 Topics: Animals; Antioxidants; Cell Count; Cell Survival; Disease Models, Animal; Drug Therapy, Combination; Glaucoma; Injections, Intraperitoneal; Intraocular Pressure; Male; Neuroprotective Agents; Rats; Rats, Wistar; Resveratrol; Retinal Ganglion Cells; Riluzole; Stilbenes; Tonometry, Ocular	2016
Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats. Neuropharmacology, 2015, Volume: 99 Topics: Administration, Intravenous; Aging; Amino Acid Transport System X-AG; Animals; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Maternal Deprivation; Memantine; Rats; Receptors, N-Methyl-D-Aspartate; Reward; Riluzole; Self Administration; Stress, Psychological	2015
A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury. Journal of neurotrauma, 2015, Nov-01, Volume: 32, Issue:21 Topics: Animals; Behavior, Animal; Cervical Cord; Disease Models, Animal; Female; Glyburide; Hypoglycemic Agents; Hypothermia, Induced; Motor Activity; Neuroprotective Agents; Rats; Rats, Long-Evans; Riluzole; Spinal Cord Injuries	2015
Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Molecular pain, 2015, Aug-28, Volume: 11 Topics: Amygdala; Animals; Arthritis; Disease Models, Animal; Hindlimb; Male; Microdialysis; Pain; Rats, Sprague-Dawley; Riluzole; Small-Conductance Calcium-Activated Potassium Channels; Stereotaxic Techniques; Vocalization, Animal	2015
Riluzole rescues alterations in rapid glutamate transients in the hippocampus of rTg4510 mice. Metabolic brain disease, 2016, Volume: 31, Issue:3 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Glutamic Acid; Hippocampus; Memory Disorders; Mice; Mice, Transgenic; Neuroprotective Agents; Riluzole	2016
In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Journal of neurochemistry, 2016, Volume: 138, Issue:1 Topics: Animals; Ataxin-3; Body Weight; Brain; Calbindins; Disease Models, Animal; Fluorescence Resonance Energy Transfer; Humans; Machado-Joseph Disease; Mice; Mice, Transgenic; Motor Activity; Neurons; Neuroprotective Agents; Prions; Reaction Time; Repressor Proteins; Riluzole; RNA, Messenger; Rotarod Performance Test	2016
Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. Molecular psychiatry, 2017, Volume: 22, Issue:2 Topics: Age Factors; Aging; Alzheimer Disease; Animals; Cognition; Cognitive Aging; Disease Models, Animal; Excitatory Amino Acid Transporter 2; Glutamic Acid; Hippocampus; Male; Memory; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Riluzole; Synaptic Transmission; Transcriptome	2017
INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model. Scientific reports, 2016, Apr-15, Volume: 6 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Models, Animal; Gene Expression; Locomotion; Motor Activity; Motor Neurons; Muscles; Mutation; Neuromuscular Junction; Phenotype; Phenylglyoxal; Riluzole; Spinal Cord; Superoxide Dismutase; Zebrafish	2016
The effect of Riluzole on functional recovery of locomotion in the rat sciatic nerve crush model. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2017, Volume: 43, Issue:5 Topics: Animals; Crush Injuries; Disease Models, Animal; Injections, Intraperitoneal; Locomotion; Male; Nerve Regeneration; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Riluzole; Sciatic Nerve; Sciatic Neuropathy; Treatment Outcome	2017
In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Experimental neurology, 2008, Volume: 212, Issue:2 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Humans; Mesenchymal Stem Cells; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Riluzole; Superoxide Dismutase	2008
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular psychiatry, 2010, Volume: 15, Issue:5 Topics: Acetates; Animals; Avoidance Learning; Behavioral Symptoms; Depression; Disease Models, Animal; Food Preferences; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamic Acid; Isotopes; Magnetic Resonance Spectroscopy; Male; Neuroglia; Neuroprotective Agents; Prefrontal Cortex; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Riluzole; RNA, Messenger; Statistics, Nonparametric; Stress, Psychological; Sucrose; Sweetening Agents	2010
Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Experimental neurology, 2009, Volume: 215, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Biophysical Phenomena; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Antagonists; Humans; Ion Channel Gating; Membrane Potentials; Mice; Mice, Transgenic; Neurons; Patch-Clamp Techniques; Riluzole; Sodium Channel Blockers; Sodium Channels; Superoxide Dismutase; Tetrodotoxin	2009
Targeting glial physiology and glutamate cycling in the treatment of depression. Biochemical pharmacology, 2009, Sep-01, Volume: 78, Issue:5 Topics: Animals; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Neuroglia; Riluzole; Stress, Psychological	2009
Riluzole disrupts autoresuscitation from hypothermic respiratory arrest in neonatal hamsters but not rats. Respiratory physiology & neurobiology, 2009, May-15, Volume: 166, Issue:3 Topics: Action Potentials; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain Stem; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hypothermia; In Vitro Techniques; Rats; Rats, Sprague-Dawley; Recovery of Function; Respiratory Center; Respiratory Mechanics; Resuscitation; Riluzole; Spinal Cord; Temperature	2009
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord. The Journal of comparative neurology, 2009, Oct-01, Volume: 516, Issue:4 Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Glutamic Acid; Kainic Acid; Malonates; Mitochondria; Motor Neuron Disease; Motor Neurons; N-Methylaspartate; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Organ Culture Techniques; Propionates; Riluzole; Spinal Cord	2009
Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice. Journal of neurophysiology, 2009, Volume: 102, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Arginine; Biophysical Phenomena; Biophysics; Calcium Channel Blockers; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; In Vitro Techniques; Interneurons; Lumbosacral Region; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Nifedipine; Patch-Clamp Techniques; Riluzole; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1	2009
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neuroscience letters, 2010, Mar-26, Volume: 472, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Disease Models, Animal; Mice; Mice, Transgenic; Mutation; Neuroprotective Agents; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1	2010
Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behavioural brain research, 2011, Jan-01, Volume: 216, Issue:1 Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Depressive Disorder; Disease Models, Animal; Emotions; Glutamic Acid; Male; Microdialysis; Olfactory Bulb; Prefrontal Cortex; Rats; Rats, Wistar; Riluzole; Statistics, Nonparametric	2011
Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. The Laryngoscope, 2010, Volume: 120, Issue:8 Topics: Animals; Dimethyl Sulfoxide; Disease Models, Animal; Endolymphatic Hydrops; Hearing Loss; Mice; Neuroprotective Agents; Reactive Oxygen Species; Riluzole	2010
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology, 2012, Volume: 219, Issue:3 Topics: Administration, Oral; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Transporter 2; Male; Mice; Mice, Inbred C57BL; Motivation; Riluzole	2012
Up-regulation of spinal glutamate transporters contributes to anti-hypersensitive effects of valproate in rats after peripheral nerve injury. Neuroscience letters, 2011, Sep-08, Volume: 502, Issue:1 Topics: Analgesics; Animals; Disease Models, Animal; Drug Therapy, Combination; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Hyperalgesia; Kainic Acid; Pain Threshold; Peripheral Nerve Injuries; Rats; Rats, Sprague-Dawley; Riluzole; Spinal Cord; Up-Regulation; Valproic Acid	2011
Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. Journal of neurophysiology, 2012, Volume: 107, Issue:1 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Disease Models, Animal; Female; Male; Mice; Motor Neurons; Neuronal Plasticity; Neuroprotective Agents; Riluzole	2012
Characterizing the effects of Eugenol on neuronal ionic currents and hyperexcitability. Psychopharmacology, 2012, Volume: 221, Issue:4 Topics: Action Potentials; Animals; Calcium Channels, L-Type; Cell Line, Tumor; Delayed Rectifier Potassium Channels; Disease Models, Animal; Dose-Response Relationship, Drug; Eugenol; Glioma; Male; Mice; Neuroblastoma; Neurons; Patch-Clamp Techniques; Pilocarpine; Rats; Rats, Sprague-Dawley; Riluzole; Seizures; Severity of Illness Index; Sodium Channels	2012
Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Experimental neurology, 2012, Volume: 233, Issue:1 Topics: Action Potentials; Analysis of Variance; Animals; Calcimycin; Calcium; Calcium Ionophores; Capillaries; Cell Count; Chlorocebus aethiops; COS Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Glyburide; Green Fluorescent Proteins; Hand Strength; Hypoglycemic Agents; Motor Activity; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Rats; Riluzole; Spinal Cord Injuries; Transfection; Treatment Outcome; TRPM Cation Channels	2012
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. BMC neuroscience, 2012, Apr-05, Volume: 13 Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Gliosis; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Riluzole; Substantia Nigra; Tyrosine 3-Monooxygenase	2012
Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry, 2012, Volume: 122, Issue:5 Topics: 8-Hydroxy-2'-Deoxyguanosine; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium-Binding Proteins; Cerebral Cortex; Deoxyguanosine; Dinoprostone; Disease Models, Animal; Encephalitis; Free Radical Scavengers; Free Radicals; Gene Expression Regulation; Humans; Ibuprofen; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Microglia; Motor Neurons; Oxidative Stress; Riluzole; Spinal Cord; Sulfasalazine; Superoxide Dismutase; Tyrosine	2012
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. Cerebellum (London, England), 2013, Volume: 12, Issue:1 Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype; Hypnotics and Sedatives; Kyphosis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Phenotype; Purkinje Cells; Pyridines; Riluzole; Serotonin Receptor Agonists; Spinocerebellar Ataxias; Zolpidem	2013
The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. Journal of neurotrauma, 2013, Feb-01, Volume: 30, Issue:3 Topics: Animals; Arachidonate 5-Lipoxygenase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Disease Models, Animal; Drug Resistance; Enzyme Inhibitors; Gene Knockout Techniques; Male; Mice; Mice, Knockout; Neuroprotective Agents; Prostaglandin-Endoperoxide Synthases; Pyrroles; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Recovery of Function; Riluzole; Spinal Cord Injuries; Tissue Array Analysis	2013
Enhanced excitability of guinea pig inferior mesenteric ganglion neurons during and following recovery from chemical colitis. American journal of physiology. Gastrointestinal and liver physiology, 2012, Nov-01, Volume: 303, Issue:9 Topics: Acetic Acid; Action Potentials; Animals; Anthracenes; Colitis; Disease Models, Animal; Electrophysiology; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Guinea Pigs; Indicators and Reagents; Intestines; Myenteric Plexus; Reaction Time; Riluzole; Trinitrobenzenesulfonic Acid	2012
Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Annals of neurology, 2013, Volume: 73, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Apomorphine; Disease Models, Animal; Dopamine Agonists; Genes, Reporter; Glycine; HSP72 Heat-Shock Proteins; Humans; Interneurons; Mice; Motor Neurons; Muscle, Skeletal; Neuromuscular Junction; Neuroprotective Agents; NF-E2-Related Factor 2; Patch-Clamp Techniques; Riluzole; Stress, Physiological; Superoxide Dismutase; Superoxide Dismutase-1; Zebrafish; Zebrafish Proteins	2013
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Feb-01, Volume: 23, Issue:3 Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Disease Progression; Electrophysiology; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; Glutamic Acid; Huntington Disease; In Vitro Techniques; Mice; Neural Pathways; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Potassium Channel Blockers; Riluzole; Tetrodotoxin	2003
Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Mar-01, Volume: 23, Issue:5 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Models, Animal; Disease Progression; Drug Resistance; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Excitatory Amino Acid Transporter 3; Glutamate Plasma Membrane Transport Proteins; Glutamic Acid; Humans; Immunoblotting; Neuroprotective Agents; Organ Specificity; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Riluzole; Spinal Cord; Superoxide Dismutase; Symporters; Synaptosomes; Transgenes	2003
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Annals of neurology, 2003, Volume: 53, Issue:4 Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Axons; Calcium Channel Blockers; Caspase 3; Caspases; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Drug Therapy, Combination; Gliosis; Mice; Mice, Transgenic; Microglia; Minocycline; Motor Neurons; Muscle Contraction; Neuroprotective Agents; Nimodipine; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1	2003
Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience, 2003, Volume: 119, Issue:3 Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anterior Horn Cells; Cell Death; Cerebral Cortex; Creatine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Male; Mice; Mice, Transgenic; Muscle, Skeletal; Neuroprotective Agents; Riluzole; Superoxide Dismutase; Treatment Outcome	2003
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & toxicology, 2003, Volume: 93, Issue:1 Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission	2003
Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology, 2003, Volume: 48, Issue:1 Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Hyperkinesis; Locomotion; Male; Mice; Neuroprotective Agents; Random Allocation; Riluzole	2003
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain research, 2003, Nov-07, Volume: 989, Issue:2 Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Immunohistochemistry; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Neurologic Examination; Neuroprotective Agents; Riluzole; Spinal Cord; Staining and Labeling; T-Lymphocytes	2003
Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. Experimental neurology, 2004, Volume: 187, Issue:2 Topics: Animals; Cell Death; Cell Survival; Dendrites; Disease Models, Animal; Drug Therapy, Combination; Female; Glial Cell Line-Derived Neurotrophic Factor; Motor Activity; Motor Neurons; Nerve Growth Factors; Nerve Regeneration; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Recovery of Function; Replantation; Riluzole; Spinal Nerve Roots; Treatment Outcome	2004
New pharmacological strategies to restore hearing and treat tinnitus. Acta oto-laryngologica, 2004, Volume: 124, Issue:4 Topics: Animals; Apoptosis; Disease Models, Animal; Hair Cells, Auditory; Hearing Loss; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Neuroprotective Agents; Peptides; Riluzole; Salicylates; Signal Transduction; Tinnitus	2004
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. Journal of neurology, 2004, Volume: 251, Issue:9 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Indans; Mice; Mice, Transgenic; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1; Survival Rate	2004
Interactions between riluzole and conventional antiepileptic drugs -- a comparison of results obtained in the subthreshold method and isobolographic analysis. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:12 Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Male; Memory; Mice; Motor Activity; Phenobarbital; Phenytoin; Riluzole; Seizures; Valproic Acid	2004
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:8 Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Excitatory Amino Acid Antagonists; Male; Medial Forebrain Bundle; Movement; Multiple System Atrophy; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Quinolinic Acid; Rats; Rats, Wistar; Riluzole; Substantia Nigra; Treatment Outcome	2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology, 2005, Volume: 194, Issue:1 Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome	2005
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of disease, 2006, Volume: 21, Issue:1 Topics: Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Genotype; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Neuroprotective Agents; Organ Culture Techniques; Riluzole; Thiazoles	2006
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:12 Topics: Adolescent; Animals; Animals, Newborn; Cattle; Cell Culture Techniques; Cell Proliferation; Disease Models, Animal; Endothelium, Vascular; Excitatory Amino Acid Antagonists; Female; Fluorescein Angiography; Humans; Hyperoxia; Infant, Newborn; Pregnancy; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Sprague-Dawley; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Riluzole; Umbilical Veins; Vascular Endothelial Growth Factor A	2005
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Experimental neurology, 2006, Volume: 198, Issue:1 Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyltransferase; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Imidazoles; Immunohistochemistry; Mice; Mice, Neurologic Mutants; Motor Activity; Motor Neurons; Neurodegenerative Diseases; Psychomotor Performance; Pyrazines; Radioimmunoassay; Riluzole	2006
Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. The European journal of neuroscience, 2006, Volume: 24, Issue:12 Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Count; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug Administration Schedule; Functional Laterality; Ganglia, Spinal; Immunohistochemistry; Nerve Regeneration; Neurites; Neurons, Afferent; Neuroprotective Agents; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Riluzole; Spinal Cord Injuries; Tubulin	2006
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. Journal of neurochemistry, 2007, Volume: 100, Issue:5 Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Aminobutyric Acid; Glutamic Acid; Hyperalgesia; Lamotrigine; Male; Microdialysis; Pain; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Long-Evans; Riluzole; Spinal Cord; Touch; Triazines	2007
Anti-glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience, 2007, Jun-15, Volume: 147, Issue:1 Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Epilepsy, Absence; Excitatory Postsynaptic Potentials; Limbic System; Male; Pilocarpine; Rats; Rats, Sprague-Dawley; Riluzole; Seizures; Sodium Oxybate; Status Epilepticus; Valproic Acid; Vesicular Glutamate Transport Protein 1	2007
Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2007, Volume: 14, Issue:7 Topics: Animals; Behavior, Animal; Disease Models, Animal; Lipid Peroxidation; Locomotion; Male; Mexiletine; Motor Activity; Phenytoin; Psychomotor Performance; Rats; Rats, Wistar; Riluzole; Sodium Channel Blockers; Spinal Cord Injuries; Statistics, Nonparametric; Time Factors; Water	2007
Evaluation of the systemic use of riluzole in post-traumatic facial nerve regeneration: experimental study in rabbits. Acta oto-laryngologica, 2007, Volume: 127, Issue:11 Topics: Animals; Disease Models, Animal; Facial Nerve Injuries; Facial Paralysis; Follow-Up Studies; Male; Nerve Regeneration; Neuroprotective Agents; Rabbits; Riluzole; Treatment Outcome	2007
Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Nov-28, Volume: 27, Issue:48 Topics: Age Factors; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Hindlimb; HSP70 Heat-Shock Proteins; Mice; Mice, Transgenic; Motor Activity; Motor Neurons; Neuromuscular Junction; Neuroprotective Agents; Riluzole; Spinal Cord; Superoxide Dismutase	2007
Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. Investigative ophthalmology & visual science, 2007, Volume: 48, Issue:12 Topics: Animals; Animals, Newborn; Blotting, Western; Dextrans; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Excitatory Amino Acid Antagonists; Fluorescein Angiography; Fluoresceins; Humans; Hypoglycemic Agents; Infant, Newborn; Injections, Intraperitoneal; Insulin; Matrix Metalloproteinases; Oxygen; Rats; Rats, Sprague-Dawley; Retinal Hemorrhage; Retinal Vessels; Retinopathy of Prematurity; Riluzole; Vascular Endothelial Growth Factor A	2007
Postnatal electrical and morphological abnormalities in lumbar motoneurons from transgenic mouse models of amyotrophic lateral sclerosis. Archives italiennes de biologie, 2007, Volume: 145, Issue:3-4 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Animals, Newborn; Biotin; Cell Differentiation; Cell Polarity; Cell Shape; Dendrites; Disease Models, Animal; Humans; Lumbosacral Region; Mice; Mice, Transgenic; Motor Neurons; Nerve Degeneration; Organ Culture Techniques; Riluzole; Sodium Channel Blockers; Sodium Channels; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1	2007
Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus? European journal of pharmacology, 1997, Aug-06, Volume: 332, Issue:2 Topics: Animals; Antiparkinson Agents; Calcium Channel Blockers; Cricetinae; Disease Models, Animal; Dystonia; Electroencephalography; Excitatory Amino Acid Antagonists; Glutamic Acid; Lamotrigine; Neuroprotective Agents; Riluzole; Triazines	1997
Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 1998, Volume: 50, Issue:1 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Female; Longevity; Male; Mice; Mice, Inbred Strains; Mice, Transgenic; Motor Activity; Neuroprotective Agents; Quality of Life; Riluzole	1998
Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. Journal of neurotrauma, 1998, Volume: 15, Issue:9 Topics: Age Factors; Animals; Battered Child Syndrome; Body Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Free Radical Scavengers; Glutamic Acid; Head Injuries, Closed; Humans; Hypoxia; Infant; Lipid Peroxidation; Male; Nerve Degeneration; Neuroprotective Agents; Pregnatrienes; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Riluzole; Time Factors	1998
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. European journal of pharmacology, 1998, Sep-04, Volume: 356, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Injections, Intravenous; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Riluzole; Sodium Channel Blockers	1998
Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology, 1998, Volume: 37, Issue:8 Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid; Huntington Disease; Male; Membrane Potentials; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Rats; Rats, Wistar; Riluzole	1998
Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3 Topics: Animals; Anticonvulsants; Disease Models, Animal; Heart Arrest; Histocytochemistry; Male; Movement Disorders; Myoclonus; Nerve Degeneration; Neuroprotective Agents; Purkinje Cells; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Riluzole	1999
Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. The Journal of thoracic and cardiovascular surgery, 1999, Volume: 117, Issue:5 Topics: Animals; Aorta, Abdominal; Apoptosis; Constriction; Cytoplasm; Disease Models, Animal; DNA; DNA Fragmentation; Female; Immunoenzyme Techniques; In Situ Nick-End Labeling; Injections, Intravenous; Ischemia; Microtubule-Associated Proteins; Motor Neurons; Necrosis; Neuroprotective Agents; Photomicrography; Rabbits; Riluzole; Spinal Cord	1999
A word of caution in extrapolating the riluzole spinal cord injury protective effects obtained in a rabbit model under ketamine anesthesia. The Journal of thoracic and cardiovascular surgery, 1999, Volume: 118, Issue:6 Topics: Anesthetics, Dissociative; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Drug Synergism; Excitatory Amino Acid Antagonists; Follow-Up Studies; Ischemia; Ketamine; Neurologic Examination; Neuroprotective Agents; Rabbits; Riluzole; Spinal Cord	1999
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology, 2000, Apr-03, Volume: 39, Issue:6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indazoles; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole	2000
Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neuroscience letters, 2000, Nov-10, Volume: 294, Issue:1 Topics: Animals; Body Temperature; Cell Count; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Gerbillinae; Hippocampus; Injections, Intraperitoneal; Ischemic Attack, Transient; Male; Neuroprotective Agents; Riluzole; Survival Rate	2000
Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology, 2000, Volume: 93, Issue:5 Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Infarction; Ketamine; Neuroprotective Agents; Paraplegia; Rabbits; Riluzole; Spinal Cord; Spinal Cord Ischemia	2000
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). Journal of the neurological sciences, 2000, Nov-01, Volume: 180, Issue:1-2 Topics: Animals; Body Weight; Disease Models, Animal; Hand Strength; Mice; Mice, Transgenic; Motor Neuron Disease; Muscle Weakness; Muscle, Skeletal; Riluzole; Survival Rate; Treatment Outcome	2000
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Immunohistochemistry; Locomotion; Male; Neuroprotective Agents; Nissl Bodies; Parkinson Disease; Parkinson Disease, Secondary; Random Allocation; Riluzole; Substantia Nigra	2002
Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience, 2002, Volume: 111, Issue:3 Topics: Acoustic Stimulation; Action Potentials; Animals; Auditory Threshold; Cell Count; Cochlea; Cochlear Nerve; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Electrophysiology; Female; Guinea Pigs; Hair Cells, Auditory; Hearing Loss, Noise-Induced; Immunohistochemistry; In Situ Nick-End Labeling; Infusion Pumps, Implantable; Neuroprotective Agents; Riluzole	2002
Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. Experimental neurology, 2002, Volume: 176, Issue:1 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Homozygote; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Neurologic Mutants; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Parkinson Disease; Potassium Channels; Potassium Channels, Inwardly Rectifying; Presynaptic Terminals; Riluzole; Substantia Nigra; Time; Tyrosine 3-Monooxygenase	2002
Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neuroscience letters, 1992, Jun-22, Volume: 140, Issue:2 Topics: Animals; Brain Ischemia; Disease Models, Animal; Electroencephalography; Gerbillinae; Ischemic Attack, Transient; Male; Rats; Riluzole; Thiazoles	1992
Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. European journal of pharmacology, 1991, Jul-09, Volume: 199, Issue:3 Topics: Animals; Anticonvulsants; Cerebral Cortex; Circadian Rhythm; Disease Models, Animal; Electromyography; Epilepsy, Absence; Male; Rats; Rats, Inbred Strains; Riluzole; Sleep; Thiazoles; Wakefulness	1991